fda announcement semaglutide As of February 21, 2025, the updated its drug shortage list, marking the injection shortage as resolved. Semaglutide injections are no longer classified as “currently in shortage,” and both 503A Drug compounders sue FDA over

Rybelsus should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus

Unmatched size and scale

It's important to remember that insurance companies often require proof that you've tried other methods to manage your weight before they will approve coverage for more intensive treatments like injections

GLP-1 medications impact the body in a variety of ways that enhance weight loss efforts

Wilson said the studys strengths include a large sample size and balanced patient characteristics, whereas its limitations include potential coding inaccuracies, potential for unmeasured confounding and limited follow-up duration

The very short plasmatic half-life represents a major limitation for the possible use of GLP-1 in the clinical setting